Tonia Poteat1, Mannat Malik2, L Leigh Ann van der Merwe3, Allanise Cloete4, Dee Adams2, Bareng A S Nonyane5, Andrea L Wirtz2. 1. Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: tonia_poteat@med.unc.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Social Health Empowerment Feminist Collective of Transgender Women of Africa, East London, South Africa. 4. Human Sciences Research Council, Cape Town, South Africa. 5. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND: The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in order to inform PrEP implementation efforts with transgender women in South Africa. METHODS: Using a community-engaged, convergent parallel mixed methods design, trained local transgender women data collectors recruited 213 transgender women participants (aged >18 years, assigned male sex at birth, and identifying as a gender different from male), via network referral and word-of-mouth in Cape Town, East London, and Johannesburg. A subset of 36 transgender women also participated in qualitative in-depth interviews. Quantitative analyses included descriptive statistics and negative binomial regression models to assess correlates of PrEP willingness. Qualitative interviews were audio-recorded, transcribed verbatim, and coded. Thematic content analysis was used to identify key themes. Quantitative and qualitative data were integrated for interpretation. FINDINGS: Participants were recruited between June 1 and Nov 30, 2018. 57 (45%) of 127 HIV-negative participants were PrEP-aware and only 14 (11%) of 129 were currently taking PrEP. HIV-negative participants experiencing social (eg, violence, poverty) and interpersonal (eg, discrimination, low transgender women community connectedness) hardship reported PrEP awareness more frequently than HIV-negative transgender women who did not. Willingness to take PrEP was low, at 56 (55%) of 102, among HIV-negative participants who were not currently taking PrEP, and negatively associated with transgender women community connectedness (multivariable prevalence ratio 0·87; 95% CI 0·77-0·99). Barriers to PrEP included taking a daily pill, side-effects, and cost. Participants urged greater education and engagement of transgender women in PrEP implementation. INTERPRETATION: South Africa is poised to scale up PrEP services for transgender women. Dedicated transgender clinics are planned to provide comprehensive care, including PrEP, for transgender women. It is critical to ensure transgender women are aware of and have accurate information about PrEP, and that health-care sites are prepared to provide quality care for transgender women. FUNDING: Gilead Sciences.
BACKGROUND: The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in order to inform PrEP implementation efforts with transgender women in South Africa. METHODS: Using a community-engaged, convergent parallel mixed methods design, trained local transgender women data collectors recruited 213 transgender womenparticipants (aged >18 years, assigned male sex at birth, and identifying as a gender different from male), via network referral and word-of-mouth in Cape Town, East London, and Johannesburg. A subset of 36 transgender women also participated in qualitative in-depth interviews. Quantitative analyses included descriptive statistics and negative binomial regression models to assess correlates of PrEP willingness. Qualitative interviews were audio-recorded, transcribed verbatim, and coded. Thematic content analysis was used to identify key themes. Quantitative and qualitative data were integrated for interpretation. FINDINGS:Participants were recruited between June 1 and Nov 30, 2018. 57 (45%) of 127 HIV-negative participants were PrEP-aware and only 14 (11%) of 129 were currently taking PrEP. HIV-negative participants experiencing social (eg, violence, poverty) and interpersonal (eg, discrimination, low transgender women community connectedness) hardship reported PrEP awareness more frequently than HIV-negative transgender women who did not. Willingness to take PrEP was low, at 56 (55%) of 102, among HIV-negative participants who were not currently taking PrEP, and negatively associated with transgender women community connectedness (multivariable prevalence ratio 0·87; 95% CI 0·77-0·99). Barriers to PrEP included taking a daily pill, side-effects, and cost. Participants urged greater education and engagement of transgender women in PrEP implementation. INTERPRETATION: South Africa is poised to scale up PrEP services for transgender women. Dedicated transgender clinics are planned to provide comprehensive care, including PrEP, for transgender women. It is critical to ensure transgender women are aware of and have accurate information about PrEP, and that health-care sites are prepared to provide quality care for transgender women. FUNDING: Gilead Sciences.
Authors: Lauren E Parmley; Tiffany G Harris; Innocent Chingombe; Munyaradzi Mapingure; Owen Mugurungi; John H Rogers; Perpetua Gozhora; Yingfeng Wu; Chesterfield Samba; Godfrey Musuka; Avi J Hakim Journal: J Int AIDS Soc Date: 2022-02 Impact factor: 5.396
Authors: Kelika A Konda; Thiago S Torres; Gabriela Mariño; Alessandra Ramos; Ronaldo I Moreira; Iuri C Leite; Marcelo Cunha; Emilia M Jalil; Brenda Hoagland; Juan V Guanira; Marcos Benedetti; Cristina Pimenta; Heleen Vermandere; Sergio Bautista-Arredondo; Hamid Vega-Ramirez; Valdilea G Veloso; Carlos F Caceres; Beatriz Grinsztejn Journal: J Int AIDS Soc Date: 2022-10 Impact factor: 6.707
Authors: Andrew Mujugira; Agnes Nakyanzi; Maria S Nabaggala; Timothy R Muwonge; Timothy Ssebuliba; Monica Bagaya; Olivia Nampewo; Oliver Sapiri; Kikulwe R Nyanzi; Felix Bambia; Rogers Nsubuga; David M Serwadda; Norma C Ware; Jared M Baeten; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771